FDA Eyes New Vaccine Composition In Response To COVID Mutations: Here's What You Need To Know

Zinger Key Points
  • This would be the first significant change to the vaccine since its original approval in December 2020.
  • As sub variants of Omicron become the dominant strand in the U.S., the FDA looks to create a new vaccine composition.

As COVID-19 continues to mutate and form new variants, the FDA is calling on the major vaccine manufacturers to create a new composition of the vaccine for adults.

What Happened: The agency has called on Moderna, Inc. MRNA, Pfizer, Inc. PFE, and Novavax, Inc. NVAX to produce the new vaccine if advisors approve the project. 

The Director of the FDA’s Center for Biologics Evaluation and Research, Dr. Peter Marks, outlines a plan where external experts would discuss which variant the new composition would focus on, Seeking Alpha reports.

This announcement comes after the FDA, on Tuesday, stated that two new sub variants of Omicron BA.4 and BA.5 have become dominant in the U.S.

Why It’s Important: This development comes as nations and companies are starting to return to pre-COVID operations. Governments all over the world have begun to ease restrictions as their populations seek a return to a more normal lifestyle.

See Also: China Loosens COVID Rules, Sending Travel, Leisure Stocks Higher: What Investors Need To Know

When the original vaccine was approved by the FDA in December 2020, it faced rejection and hesitancy from various groups around the U.S. If vaccine manufacturers and the FDA move forward with this new composition, it will potentially be matched with additional hesitancy.

Since the original vaccine was approved by the FDA in December 2020, there have been no significant changes to the composition of the immunization.

On the contrary, many scientists and doctors will argue that this new composition will likely be the best way to protect oneself from COVID's ongoing mutations.

What’s Next: On June 28, the FDA Vaccines and Related Biologics Advisory Committee met and invited Moderna, Pfizer, and Novax to present their ideas on what a possible new composition could be like.

The FDA advisors will then review all opinions and facts to reach a decision on whether to move forward with the project. An advisor vote will take place in July.

If the advisors decide to move forward with the project, the agency is targeting the new composition to be completed and approved for adults by October. 

Photo: Courtesy Diverse Stock Photos on flickr

Posted In: COVIDvaccineBiotechGovernmentNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.